NASDAQ$ATEC
Alphatec Holdings Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
ATEC reported results for Q4 2021 and Full Year 2021, highlighted by revenue growth and strategic advancements.
Alphatec Holdings, Inc. reported a strong Q4 and full year 2021, with record revenue and significant growth driven by the adoption of innovative spine surgery solutions and the integration of EOS imaging. The company's focus on surgeon trust and clinically distinct technology contributed to its sector-leading growth.
- ATEC reported the highest revenue on record for 2021.
- ATEC's lateral procedures delivered over 40% of Q4 revenue growth, driven by the adoption of Prone Trans-Psoas (PTP) Technique.
- ATEC trained over 400 surgeons in 2021, contributing to a 23% increase in surgeon users in Q4 compared to the prior year.
- ATEC generated $12.8 million in EOS-related revenue, showing momentum in sales, product development, and data management.
Headline financials
Revenue & EPS history
Alphatec · Revenue · Quarterly
$74M
Revenue by segment
Alphatec · $104M total across 1 segment · Q3 2023
- Surgical Revenue$104M—100.0%
Forward guidance
The Company continues to expect total revenue for the fiscal year ended December 31, 2022, to approximate $305 million, reflecting growth of approximately 25% compared to the full year 2021. This includes organic revenue growth of 23% and approximately $45 million of revenue related to EOS imaging.
Tailwinds
- Total revenue for fiscal year 2022 is expected to approximate $305 million.
- Projected revenue reflects growth of approximately 25% compared to the full year 2021.
- Organic revenue growth of 23% is anticipated.
- Approximately $45 million of revenue is expected from EOS imaging.
- The company will continue to expand the lateral market with PTP, advance our distribution network, and place EOS imaging systems while driving portfolio-wide adoption.
Headwinds
- Uncertainty of success in developing new products or products currently in the pipeline.
- Uncertainties in the Company’s ability to execute upon its strategic operating plan.
- Failure to achieve acceptance of the Company’s products by the surgeon community.
- Failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process.
- Uncertainties and risks related to the integration of EOS imaging, S.A.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-1.5%
Avg return
Earnings day
-1.4%
Avg return
5 days after
-0.1%
Avg return
30 days after
45%
29 / 64 earnings
Positive
+44.8%
Q3 2024
Best reaction
-43.2%
Q2 2010
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.9% | -27.1% | -23.3% | |
| Q4 2025 | +0.5% | -3.3% | -21.5% | |
| Q3 2025 | -0.8% | +17.8% | +36.7% | |
| Q1 2025 | +2.4% | +2.2% | +2.2% | |
| Q4 2024 | +9.6% | +6.1% | -7.9% | |
| Q3 2024 | +44.8% | +54.2% | +93.4% | |
| Q2 2024 | -32.8% | -33.7% | -30.2% | |
| Q1 2024 | -20.2% | -13.3% | -22.7% | |
| Q4 2023 | -7.4% | -11.1% | -8.6% | |
| Q3 2023 | +4.7% | -1.5% | +20.8% | |
| Q2 2023 | -7.1% | -10.4% | -5.2% | |
| Q1 2023 | +3.1% | +3.8% | +4.5% | |
| Q4 2022 | +1.6% | +7.9% | +6.3% | |
| Q3 2022 | -1.5% | -1.4% | +9.5% | |
| Q2 2022 | -0.2% | -3.8% | -10.9% | |
| Q1 2022 | -16.1% | -27.7% | -34.0% | |
| Q4 2021 | +3.1% | +3.4% | +4.4% | |
| Q3 2021 | -2.2% | -8.2% | -18.7% | |
| Q2 2021 | +2.4% | -5.8% | -0.2% | |
| Q1 2021 | -2.0% | -9.1% | -8.3% | |
| Q4 2020 | -7.6% | +4.2% | -2.1% | |
| Q3 2020 | +9.4% | +4.7% | +22.1% | |
| Q2 2020 | +21.8% | +5.6% | +3.1% | |
| Q1 2020 | -8.0% | -13.9% | +5.7% | |
| Q4 2019 | -8.4% | -20.8% | -47.2% | |
| Q3 2019 | +15.2% | +16.1% | +18.1% | |
| Q2 2019 | +9.3% | +8.5% | +26.2% | |
| Q1 2019 | +5.4% | +15.8% | +8.8% | |
| Q4 2018 | +14.7% | +16.6% | +22.1% | |
| Q3 2018 | -1.7% | -5.6% | -13.5% | |
| Q2 2018 | +4.7% | +15.0% | +28.1% | |
| Q1 2018 | -2.0% | -0.9% | -1.1% | |
| Q4 2017 | +0.9% | -5.0% | +1.2% | |
| Q3 2017 | -0.8% | -0.6% | -30.5% | |
| Q2 2017 | +2.4% | +2.4% | +40.2% | |
| Q1 2017 | +1.9% | +0.0% | -4.8% | |
| Q4 2016 | -16.0% | -27.0% | -45.8% | |
| Q3 2016 | -15.8% | -8.0% | -12.8% | |
| Q2 2016 | +2.5% | +0.0% | -6.5% | |
| Q1 2016 | -11.8% | — | — | |
| Q4 2015 | -13.8% | — | — | |
| Q3 2015 | +5.8% | — | — | |
| Q2 2015 | -42.6% | — | — | |
| Q1 2015 | +1.4% | — | — | |
| Q4 2014 | +7.4% | — | — | |
| Q3 2014 | -0.7% | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | +2.3% | — | — | |
| Q4 2013 | +22.3% | — | — | |
| Q3 2013 | -0.5% | — | — | |
| Q2 2013 | -3.9% | — | — | |
| Q1 2013 | -3.2% | — | — | |
| Q4 2012 | +2.6% | — | — | |
| Q3 2012 | -1.8% | — | — | |
| Q2 2012 | -2.5% | — | — | |
| Q1 2012 | -7.4% | — | — | |
| Q4 2011 | -0.5% | — | — | |
| Q3 2011 | -5.6% | — | — | |
| Q2 2011 | -10.4% | — | — | |
| Q1 2011 | +3.7% | — | — | |
| Q4 2010 | +0.4% | — | — | |
| Q3 2010 | -9.6% | — | — | |
| Q2 2010 | -43.2% | — | — | |
| Q1 2010 | +6.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro